Prostate Adenocarcinoma Clinical Trials

42 studies are recruiting for prostate adenocarcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance

   This phase II trial studies the side how well hyperpolarized carbon C 13 pyruvate (HP C-13 pyruvate) magnetic resonance imaging (MRI) works in monitoring patients with prostate cancer on active surveillance who have not received treatment. Diagnostic procedures, such as MRI, may help visualize HP C…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   University of California, San Francisco

   See if you can join NCT03933670 on ClinicalTrials.gov

2. Nutrition and Exercise Interventions for Androgen Deprivation Therapy-Induced Obese Frailty in Elderly and Non-Elderly Survivors of Advanced Prostate Cancer

   This trial studies how well nutrition and exercise interventions work in reducing androgen deprivation therapy-induced obese frailty in prostate cancer survivors. Individualized nutrition and exercise advice for prostate cancer patients on androgen deprivation therapy may help to reduce obese frail…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Roswell Park Cancer Institute, Buffalo, New York

   Run by

   Roswell Park Cancer Institute

   See if you can join NCT03880422 on ClinicalTrials.gov

3. PSMA PET Response Guided SabR in High Risk Pca

   Sequential cohort evaluation of ideal timing of imaging and treatment spacing to discern maximal PSMA (Prostate specific membrane antigen) PET (Positron Emission Tomography) response (PSMA-11 68Ga, Illucix) for adaptation of dominant intra-prostatic lesion tumor boost dose

   Stage

   Phase 1

   Ages

   18 to 99

   Site

   University of Texas Southwestern Medical Center, Dallas, Texas

   Locations

   2 in total

   Run by

   University of Texas Southwestern Medical Center

   See if you can join NCT06044857 on ClinicalTrials.gov

4. Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy

   Male adults with a confirmed diagnosis of prostate adenocarcinoma who meet criteria for localized high risk prostate cancer according to the NCCN guidelines and who are eligible for prostatectomy will be invited to participate. Criteria for high-risk prostate cancer include patients with preoperati…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey

   Locations

   3 in total

   Run by

   Hackensack Meridian Health

   See if you can join NCT06798558 on ClinicalTrials.gov

5. Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

   This phase II trial studies how well a short course of androgen deprivation therapy (ADT) with relugolix works in increasing expression of prostate-specific membrane antigen (PSMA) and improving diagnostic imaging with PSMA positron emission tomography (PET)/computed tomography (CT) in patients wit…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Mayo Clinic in Arizona, Scottsdale, Arizona

   Run by

   Mayo Clinic

   See if you can join NCT07025369 on ClinicalTrials.gov

6. Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

   This phase II trial compares the effect of relugolix to leuprolide on cardiac function and performance in patients with prostate cancer. Androgen deprivation therapy (ADT) has been a key component for the treatment of advanced prostate cancer for decades. The term androgen deprivation therapy means…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Run by

   Ohio State University Comprehensive Cancer Center

   See if you can join NCT06330805 on ClinicalTrials.gov

7. Impact of Intraoperative ICG on Functional Outc in RARP

   This is a pilot, 3 phases open-label feasibility study with the 3rd phase consisting of randomized 2-arm intervention trial, to assess the systematic use of indocyanine green (ICG) in subjects with prostate adenocarcinoma during robot-assisted radical prostatectomy and its impact on sexual function…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Chao Family Comprehensive Cancer Center University of California, Irvine, Orange, California

   Run by

   University of California, Irvine

   See if you can join NCT06446648 on ClinicalTrials.gov

8. Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance

   This investigator-initiated, prospective study evaluates the diagnostic utility of rhPSMA-7.3 (¹⁸F) PET/CT (flotufolastat F18, marketed as POSLUMA®) in men with biopsy-proven, low-risk or favorable intermediate-risk prostate cancer managed with active surveillance. The study aims to determine wheth…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Mount Sinai Hospital / Icahn School of Medicine at Mount Sinai, New York, New York

   Run by

   Icahn School of Medicine at Mount Sinai

   See if you can join NCT07285057 on ClinicalTrials.gov

9. Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)

   This is a single-arm, multicenter open label, international, phase II study of Bipolar Androgen Therapy (BAT) plus Radium-223 (RAD) in men with metastatic castration-resistant prostate cancer (mCRPC). Men with mCRPC with progressive disease (radiographically and/or biochemically) who have been trea…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Amber Michalik, Baltimore, Maryland

   Locations

   2 in total

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT04704505 on ClinicalTrials.gov

10. Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

    This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug ci…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Anchorage Associates in Radiation Medicine, Anchorage, Alaska

    Locations

    133 in total

    Run by

    SWOG Cancer Research Network

    See if you can join NCT05806515 on ClinicalTrials.gov

11. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Beverly Hills Cancer Center, Beverly Hills, California

    Locations

    39 in total

    Run by

    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

12. Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement

    This purpose of this study is to examine the placement of proton spots during pencil beam scanning proton therapy for low and intermediate risk prostate cancer. The researchers will test a unique technique called "Spot Delete" to control the placement of spots during treatment planning. They will a…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Thompson Proton Center, Knoxville, Tennessee

    Run by

    Covenant Health Cancer Center

    See if you can join NCT06200259 on ClinicalTrials.gov

13. Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

    This phase II trial tests how well risk based de-escalated hormone therapy (i.e., fewer treatments) with radiation works in treating patients with prostate cancer. Androgen deprivation therapy (ADT), such as gonadotropin-releasing hormone analogs (LHRH) and abiraterone acetate (Zytiga), lower the a…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Mayo Clinic in Arizona, Scottsdale, Arizona

    Run by

    Mayo Clinic

    See if you can join NCT06369610 on ClinicalTrials.gov

14. Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

    This clinical trial investigates the change in prostate-specific membrane antigen (PSMA) expression in response to hormonal therapy in both, Castration Sensitive Prostate Cancer (CSPC) and Castration Resistant Prostate Cancer (CRPC), and whether this change in PSMA expression changes tumor staging …

    Stage

    Phase 4

    Ages

    18 and older

    Site

    OHSU Knight Cancer Institute, Portland, Oregon

    Run by

    OHSU Knight Cancer Institute

    See if you can join NCT05919329 on ClinicalTrials.gov

15. ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials

    This study will follow men with metastatic castration resistant prostate cancer throughout their standard of care treatment for their disease to determine if the presence of different genes or proteins can predict which patients respond to the cancer treatment they receive. As tumors grow and begin…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Locations

    3 in total

    Run by

    Duke University

    See if you can join NCT06141993 on ClinicalTrials.gov

16. A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer

    Molecular Imaging (MI) uses tracers which emit radiation to provide clinically valuable imaging for patient with cancer. Most current MI agents utilize Fluorine 18 or Gallium 68 as the positron emitter for PET imaging. However, these isotopes have short half-lives which limit the geographic distrib…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Hoag Memorial Hospital Presbyterian, Irvine, California

    Run by

    Hoag Memorial Hospital Presbyterian

    See if you can join NCT06736054 on ClinicalTrials.gov

17. Customized TULSA-PRO Ablation Registry

    This patient registry will capture data from patients who have been or who are undergoing the transurethral ultrasound ablation (TULSA) procedure as part of their routine clinical care. The registry will shed light on real-world outcomes of safety and efficacy of the procedure and understand how a …

    Stage

    Not phased

    Ages

    18 and older

    Site

    RadNet's Liberty Pacific West Hills Facility, West Hills, California

    Locations

    5 in total

    Run by

    Profound Medical Inc.

    See if you can join NCT05001477 on ClinicalTrials.gov